Product Description
Mechanisms of Action: Voltage-Gated Chlorine Channel Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mallinckrodt
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Duodenal Ulcer|Osteoarthritis|Arthritis, Rheumatoid|Stomatitis|Head and Neck Cancer|Mucositis|Hypertension, Portal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SCMP-8811-202 | P2 |
Terminated |
Head and Neck Cancer|Mucositis|Stomatitis |
2016-07-01 |
23% |
| SU0621 | P2 |
Completed |
Arthritis, Rheumatoid|Duodenal Ulcer|Osteoarthritis |
2009-04-01 |
|
| SPH0721 | P2 |
Terminated |
Hypertension, Portal |
2009-02-01 |
|
| JapicCTI-152763 | P2 |
Completed |
Unknown |
None |